<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01100996</url>
  </required_header>
  <id_info>
    <org_study_id>2009/168</org_study_id>
    <nct_id>NCT01100996</nct_id>
  </id_info>
  <brief_title>Anti-inflammatory Effects of Enriched Enteral Nutrition During Human Experimental Endotoxemia</brief_title>
  <acronym>VIHE</acronym>
  <official_title>The Effect of Enriched Enteral Nutrition on Inflammation and Sub-clinical Organ Dysfunction During Human Endotoxemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      During sepsis and septic shock the immune response can be overwhelming leading to excessive
      tissue damage, organ failure and death. Ideally, the inflammatory response is modulated
      leading to both adequate protection to invading pathogens as well as limitation of an
      exuberant immune response. In the last years, experimental evidence has been accumulating
      that enteral administration of lipid-enriched nutrition attenuates inflammation and preserves
      organ integrity in several inflammatory models. The current study investigates the
      immune-modulating potential of enriched enteral nutrition in a human setting of experimental
      endotoxemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>circulating cytokines</measure>
    <time_frame>several time points from LPS administration until 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>markers for sub-clinical organ damage (kidney, endothelium, intestine)</measure>
    <time_frame>several time points from LPS administration until 24 h</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Endotoxemia</condition>
  <arm_group>
    <arm_group_label>fasted control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Volunteers are fasted for 10 hours and subjected to experimental endotoxemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control feeding</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Volunteers are fed a control nutrition starting 1 hour prior to LPS administration until 6 hours after LPS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>enriched feeding</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>volunteers receive the investigational feeding starting 1 hour prior to LPS administration until 6 hours after LPS</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control enteral nutrition</intervention_name>
    <description>This feeding consists of 20en% fat, 16en% protein and 49en% carbohydrates</description>
    <arm_group_label>control feeding</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>enriched enteral feeding</intervention_name>
    <description>This feeding contains 46 energy percent (en%) fat, 24en% protein and 30en% carbohydrates and is enriched with phospholipids.</description>
    <arm_group_label>enriched feeding</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 and ≤ 35 yrs

          -  Male

          -  Written informed consent

          -  non-smoking

        Exclusion Criteria:

          -  Use of any medication (e.g. NSAID's, antibiotics, gastrointestinal motility altering
             medicine, corticosteroids)

          -  Smoking in the past year

          -  History, signs or symptoms of cardiovascular disease

          -  (Family; first degree) history of cerebrovascular disease

          -  Previous vagal collapse

          -  Hypertension (defined as RR systolic &gt; 160 or RR diastolic &gt; 90)

          -  Hypotension (defined as RR systolic &lt; 100 or RR diastolic &lt; 50)

          -  Renal impairment (defined as plasma creatinin &gt;120 μmol/l)

          -  Liver enzyme abnormalities ( ASAT &gt; 60 U/L, ALAT &gt; 75 U/L, Gamma-GT &gt; 60 U/L)

          -  Positive hepatitis serology

          -  Positive HIV test

          -  Allergy to milk and/or soy proteins
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Van der Hoeven, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Intensive Care Medicine, Radboud University Nijmegen Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Luyer MD, Greve JW, Hadfoune M, Jacobs JA, Dejong CH, Buurman WA. Nutritional stimulation of cholecystokinin receptors inhibits inflammation via the vagus nerve. J Exp Med. 2005 Oct 17;202(8):1023-9. Epub 2005 Oct 10.</citation>
    <PMID>16216887</PMID>
  </reference>
  <reference>
    <citation>Luyer MD, Derikx JP, Beyaert R, Hadfoune M, van Kuppevelt TH, Dejong CH, Heineman E, Buurman WA, Greve JW. High-fat nutrition reduces hepatic damage following exposure to bacterial DNA and hemorrhagic shock. J Hepatol. 2009 Feb;50(2):342-50. doi: 10.1016/j.jhep.2008.08.025. Epub 2008 Nov 8.</citation>
    <PMID>19070388</PMID>
  </reference>
  <reference>
    <citation>de Haan JJ, Lubbers T, Hadfoune M, Luyer MD, Dejong CH, Buurman WA, Greve JW. Postshock intervention with high-lipid enteral nutrition reduces inflammation and tissue damage. Ann Surg. 2008 Nov;248(5):842-8. doi: 10.1097/SLA.0b013e318188752c.</citation>
    <PMID>18948813</PMID>
  </reference>
  <reference>
    <citation>Lubbers T, Luyer MD, de Haan JJ, Hadfoune M, Buurman WA, Greve JW. Lipid-rich enteral nutrition reduces postoperative ileus in rats via activation of cholecystokinin-receptors. Ann Surg. 2009 Mar;249(3):481-7. doi: 10.1097/SLA.0b013e318194d187.</citation>
    <PMID>19247038</PMID>
  </reference>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2010</study_first_submitted>
  <study_first_submitted_qc>April 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2010</study_first_posted>
  <last_update_submitted>June 6, 2011</last_update_submitted>
  <last_update_submitted_qc>June 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. J.G. van der Hoeven</name_title>
    <organization>Radboud University Nijmegen Medical Center</organization>
  </responsible_party>
  <keyword>enteral nutrition</keyword>
  <keyword>endotoxemia</keyword>
  <keyword>innate immunity</keyword>
  <keyword>nutritional anti-inflammatory pathway</keyword>
  <keyword>intestinal damage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endotoxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

